Much-Needed Clarification and Guidance on Cell-Based Therapies for Musculoskeletal Disorders.
Much-Needed Clarification and Guidance on Cell-Based Therapies for Musculoskeletal Disorders.
复制标题
肌肉骨骼疾病细胞疗法急需的澄清和指导。
DOI：
10.1002/jbmr.3841
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Longaker,MichaelT
中科院分区：
文献类型：
--
作者：
Murphy,MatthewP;Wan,DerrickC;Longaker,MichaelT
Within the last 30 years, there have been many advancements within the field of stem cell biology, and controversies regarding their clinical implementation make the joint American SocietyforBoneandMineralResearch (ASBMR) andtheOrthopaedic Research Society (ORS) Task Force by O’Keefe and colleagues especially timely.(1) Early descriptions of “the mesenchymal stem cell” by Friedenstein (2) and colleagues and later by Caplan (3) characterized these progenitors as a nonhematopoietic cell expanded by in vitro culture with the ability to self-renew and differentiate along multiple lineages. Since then, our understanding and ability to isolate pure populations of tissue-resident stem cells has allowed for the more accurate determination of key cellular signaling pathways.(4, 5) The ability to induce pluripotency creating induced pluripotent stem cells (iPSCs) has further opened the door for use of progenitor cells in disease modeling, drug discovery, and regenerative strategies.(6) Finally, postnatal tissues such as bone marrow, periosteum, fat, brain, skin, and umbilical cord blood have been shown to harbor tissue resident progenitor cells, such as the skeletal stem cell,(5) with significant promise for potential clinical application.(7) The present report broaches five main subjects: 1) limitations of cell-based therapies according to their cellular source (encompassing iPSCs, embryonic stem cells [ESCs], bone marrow stromal cells [BMSCs], skeletal stem cells [SSCs], nonskeletal-derived mesenchymal stem cells [MSCs], and differentiated skeletal cells); 2) utility of cell-derived products based on cellular source (encompassing platelet-rich plasma [PRP], conditioned medium, and extracellular vesicles [EV]); 3) tissue-specific animal models of cell-based therapies (focusing on bone, cartilage, intervertebral disc [IVD], meniscus, and tendon/ligament); 4) criteria for interpreting cell-based regenerative experiments; and 5) recommendations for preclinical and clinical cell-based therapies (preclinical animal models and human clinical trials).The Task Force report bridges basic science and clinical practice. The ability for researchers to understand the clinical relevance and the practicing physician to understand the basic science will undoubtedly improve research outcomes and clinical practice. The Task Force report also allows for a more uniform understanding and improved ability to compare research outcomes by ensuring that key stakeholders involved in preclinical and clinical trials are aware of the recommendations. Of note, the Task Force report recommends that before Federal Drug Agency (FDA) approval there should be reproducibility across multiple institutions through shared collaboration and communication.
